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  ABSTRACT 
  Objective      To evaluate the effect of different 
concomitant disease modifying antirheumatic drugs 
(DMARDs) on the persistence with antitumour necrosis 
factor (anti-TNF) therapies in patients with rheumatoid 
arthritis (RA).   
  Method      This analysis included 10 396 patients with 
RA registered with the British Society for Rheumatology 
Biologics Register, a prospective observational cohort 
study, who were starting their ﬁ  rst anti-TNF therapy 
and were receiving one of the following DMARD 
treatments at baseline: no DMARD (n=3339), 
methotrexate (MTX) (n=4418), leﬂ  unomide (LEF) 
(n=610), sulfasalazine (SSZ) (n=308), MTX+SSZ 
(n=902), MTX+ hydroxychloroquine (HCQ) (n=401) 
or MTX+SSZ+HCQ (n=418). Kaplan–Meier survival 
analysis was used to study the persistence with anti-
TNF therapy in each DMARD subgroup up to 5 years. 
Multivariate Cox proportional hazard models, stratiﬁ  ed by 
anti-TNF used and start year and adjusted for a number of 
potential confounders, were used to compare treatment 
persistence overall and according to the reason for 
discontinuation between each of the DMARD subgroups, 
using MTX as reference.   
  Results      One-year drug survival (95% CI) for the ﬁ  rst 
anti-TNF therapy was 71% (71% to 72%) but this dropped 
to 42% (41% to 43%) at 5 years. Compared with MTX, 
patients receiving no DMARD, LEF or SSZ were more 
likely to discontinue their ﬁ  rst anti-TNF therapy while 
patients receiving MTX in combination with other 
DMARDs showed better treatment persistence.   
  Conclusions      These results support the continued use 
of background DMARD combinations which include MTX. 
Consideration should be given to the discontinuation of 
LEF and SSZ monotherapy at the time anti-TNF therapies 
are started, with the possible exception of the SSZ+ETN 
 combination.      
  INTRODUCTION 
  Antitumour necrosis factor (anti-TNF) therapies 
are now routinely used in the management of 
rheumatoid arthritis (RA) in patients for whom 
traditional disease-modifying antirheumatic 
drugs (DMARDs) have failed. The efﬁ  cacy  of 
anti-TNF therapies has been evaluated in several 
randomised controlled trials (RCTs). Recent sys-
tematic reviews and meta-analyses have shown 
their initial efﬁ   cacy compared with placebo.    1     –      3    
In addition, a meta-analysis of 13 RCTs has 
demonstrated better response to three anti-TNF 
therapies (etanercept (ETN), inﬂ  iximab (INF) and 
adalimumab (ADA)) when used in combination 
with methotrexate (MTX) than when used as 
monotherapies.    1    Results from observational stud-
ies have also suggested better response to ETN 
and ADA when prescribed with MTX or with 
other DMARDs compared with monotherapies.    4    
In clinical practice, although MTX is the DMARD 
most commonly used with anti-TNF therapies, 
patients who have a contraindication or intoler-
ance to MTX may still be prescribed anti-TNF 
therapies either in monotherapy or in combina-
tion with other DMARDs.    4    Further clinical tri-
als and observational studies have suggested the 
beneﬁ  ts of combined treatment with other con-
comitant DMARDs including sulfasalazine (SSZ) 
and hydroxychloroquine (HCQ).    5        6    The suggested 
beneﬁ  t of combined treatment with leﬂ  unomide 
(LEF)    7     –      11    has also been reported, although the 
results have not been consistent. There has also 
been a concern about the safety of this latter 
combination,    12    with a particular reference to an 
increased occurrence of dermatological and auto-
immune adverse effects. A further proportion of 
patients will receive anti-TNF therapies in combi-
nation with more than one DMARD, which may 
or may not include MTX. The beneﬁ  ts or safety of 
continuing these combinations of DMARDs with 
anti-TNF therapy has not been studied in detail. 
  Treatment continuation rates (or persistence 
rates) are an effective tool to measure both the 
effectiveness and safety of a treatment.    13    The 
effect of concurrent DMARDs, primarily MTX, on 
anti-TNF persistence in RA has been   examined in 
a number of recent studies,    7        14     –      18    and the results 
suggested better persistence with anti-TNF ther-
apies when used with DMARDs. However, a 
majority of these studies were not able to look at 
individual DMARDs other than MTX owing to 
small sample size. Therefore, using data from the 
large British Society for Rheumatology Biologics 
Register (BSRBR), this study aimed to compare 
the effects of different concomitant DMARDs, 
either alone or in combination, on the   persistence 
with anti-TNF therapies in RA.   
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prespeciﬁ  ed list which included inefﬁ  cacy, adverse events and 
‘other’ reasons.   
  Data  analysis 
  BSRBR data up to June 2009 were used for this analysis. All 
patients with RA registered with the BSRBR who had started 
treatment with their ﬁ  rst course of anti-TNF therapy (ETN, INF 
or ADA) within 6 months of registration were eligible for inclu-
sion in the analysis and classiﬁ  ed according to their concomi-
tant DMARD treatments at baseline. Patients receiving the most 
common DMARD co-therapies (deﬁ  ned as >2.5% of the total 
cohort) were included in the current analysis. Patients for whom 
no follow-up information was returned (approximately 2.5%) 
were excluded. 
  The primary outcome was persistence with a ﬁ  rst anti-TNF 
therapy, which was deﬁ  ned as the length of time the patients 
continued to receive their ﬁ  rst anti-TNF therapy.    22    Patients were 
censored at treatment stop date, date of death or date of the last 
follow-up, whichever came ﬁ  rst. Temporary stops of <90 days 
(which is common for surgery or certain adverse events—for 
example, infection), after which the patients restarted the same 
anti-TNF therapy, were not included and counted as continu-
ous use of the drug. Kaplan–Meier survival curves were used 
to describe the persistence with anti-TNF therapy. Univariate 
and multivariate Cox proportional hazard models were used to 
compare anti-TNF discontinuation rates between each concomi-
tant DMARD treatment group and concomitant treatment with 
MTX (the reference group). Covariates included demographic 
characteristics (age (years), gender, presence of comorbidities 
(none/one/more than one), current smoking (yes/no)), baseline 
disease characteristics (number of previous DMARDs, disease 
duration (years), baseline DAS28 and baseline HAQ). The mod-
els were also stratiﬁ  ed by the year of start of anti-TNF therapy, 
and the anti-TNF therapy used. The primary analysis included 
all anti-TNF therapies together. A secondary analysis was per-
formed for each anti-TNF therapy separately. In all cases three 
models were developed: (1) any stop, (2) stopping for inefﬁ  cacy 
and (3) stopping for adverse events. The results are presented 
  PATIENTS  AND  METHODS 
  Patient  population 
  Patients for this analysis were selected from the BSRBR.    19    The 
BSRBR is a national prospective observational cohort study based 
in the UK. The register was established in 2001 by the British 
Society for Rheumatology (BSR) with the main aim of assessing 
the long-term safety of biological treatments in RA. In the UK, 
anti-TNF treatments for RA are reserved for those patients with 
a 28-joint count Disease Activity Score (DAS28)    20    >5.1 despite 
previous treatment with at least two standard DMARDs (one 
of which must include MTX). The BSRBR aimed to recruit 4000 
patients starting each of the three anti-TNF therapies (ETN, INF 
and ADA); powered on an ability to detect a doubling in the risk 
of lymphoma compared with standard DMARD treatments. 
Owing to differences in the availability of each of these three 
drugs, recruitment to the study was not constant over time and 
the 4000 target was subsequently achieved for ETN, INF and 
ADA in 2005, 2007 and 2008, respectively. Ethical approval for 
the BSRBR was given by the North West Multi-centre Research 
Ethics Committee in December 2000. All patients provided 
written informed consent.   
  Baseline  data 
  At the start of the anti-TNF treatment, and following patient 
consent, the rheumatology consultant was asked to complete 
a consultant baseline questionnaire that collected data on 
demographics, DAS28, current and previous DMARD treat-
ments, comorbidities and smoking status. The baseline Health 
Assessment Questionnaire (HAQ) adapted for use in a UK pop-
ulation    21    was also collected from the patient.   
  Follow-up 
  Follow-up questionnaires were sent to the consultants every 
6 months for 3 years and annually thereafter. Consultant fol-
low-up questionnaires collected data on any changes to anti-
TNF therapies, including start and stop dates and the reasons 
for stopping the drug (if the patient stopped treatment). The 
consultant was asked to assign the reasons for stopping from a 
  Table  1      Baseline  characteristics  
 Characteristics *  Total  cohort 
  Concomitant DMARD treatment at baseline 
 None   MTX   SSZ   LEF   MTX+SSZ   MTX+HCQ   MTX+SSZ+HCQ 
Patients, n (%) 10 396 (100.0) 3339 (32.1) 4418 (42.5) 308 (3.0) 610 (5.9) 902 (8.7) 401 (3.9) 418 (4.0)
Demographic 
characteristics
Mean age 
(SD) (years)
     56.1  (12.3)   58.2  (12.0)   55.3  (12.9) 56.9  (11.8)  57.1  (11.4)  53.7  (12.7)  54.1  (12.5)  52.9  (12.5)
Female, n (%)     7915 (76) 2605 (78) 3358 (76) 228 (74) 469 (77) 628 (70) 326 (81) 301 (72)
Current smokers, 
n (%)
    2271 (22)   696 (21)   947 (21) 62 (20) 139 (23) 212 (24)   99 (25) 116 (28)
Comorbidities,  †  
n (%)
    6253 (60) 2212 (66) 2557 (58) 190 (62) 371 (61) 478 (53) 214 (53) 231 (55)
Disease 
characteristics
Mean disease 
duration (SD) (years)
     13.3  (9.7)   14.4  (9.8)   13.3  (9.6) 13.8  (9.6)  14.5  (9.7)  10.3  (9.1)  11.2  (9.6)  10.1  (8.3)
Mean number of 
previous DMARDs 
(SD)
      3.9  (1.7)    4.4  (1.7)    3.7  (1.6) 3.6  (1.5)   4.5  (1.6)   2.8  (1.1)   3.6  (1.3)   3.6  (1.1)
Mean  DAS28  (SD)       6.6  (1.0)    6.7  (1.0)    6.5  (1.0) 6.6  (1.0)   6.5  (0.9)   6.5  (1.0)   6.4  (1.0)   6.5  (0.9)
Mean  HAQ  (SD)       2.0  (0.6)    2.1  (0.6)    2.0  (0.6) 2.0  (0.6)   2.0  (0.6)   1.9  (0.6)   1.9  (0.6)   2.0  (0.6)
Anti-TNF therapy ETN, n (%)     3605 (35) 1921 (58)   925 (21) 121 (39) 244 (40) 221 (25)   91 (23)   82 (20)
INF, n (%)     3136 (30)   255 (8) 2188 (50) 28 (9) 105 (17) 295 (33) 126 (31) 139 (33)
ADA, n (%)     3655 (35) 1163 (35) 1305 (30) 159 (52) 261 (43) 386 (43) 184 (46) 197 (47)
      *HAQ was available for 95% of the patients; current smoking and disease duration were available for 99% of the patients; no missing values were found in the rest of the baseline 
characteristics. 
  †  Comorbidities included one or more of the following: angina, hypertension, myocardial infarction, stroke, epilepsy, asthma, chronic obstructive pulmonary disease, peptic ulcers, liver 
disease, renal disorder, demyelination, diabetes, hyperthyroidism, depression or a history of tuberculosis or cancer. 
  ADA, adalimumab; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drugs; ETN, etanercept; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; 
INF, inﬂ  iximab; LEF, leﬂ  unomide; MTX, methotrexate; SSZ, sulfasalazine.     
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as hazard ratios and 95% CIs. STATA 10.1 software was used 
for all statistical analyses (STATA Corporation, College Station, 
Texas, USA).     
  RESULTS 
  Baseline  characteristics 
  By June 2009, 10 396 patients registered with the BSRBR met 
the inclusion criteria for the current analysis (3605 ETN, 3136 
INF and 3655 ADA). Of these, 3339 (32.1%) were receiving 
their anti-TNF as monotherapy (ie, no concurrent DMARD 
at baseline), 4418 (42.5%) in combination with MTX, 610 
(5.9%) with LEF, 308 (3.0%) with SSZ, 902 (8.7%) with 
MTX+SSZ, 401 (3.9%) with MTX+HCQ and 418 (4.0%) with 
MTX+SSZ+HCQ. 
  Baseline characteristics of the entire cohort and stratiﬁ  ed by 
baseline DMARD combination are presented in  table 1 .   Seventy-
six per cent of patients were female and the mean (SD) age was 
56.1 (12.3) years. About one-ﬁ  fth of the patients were current 
smokers, while about 60% of them had other comorbidities in 
addition to RA. The patients had received a mean (SD) of 3.9 
(1.7)   DMARDs previously. The patients had a mean (SD) disease 
duration of 13.3 (9.7) years. The mean (SD) baseline DAS28 was 
6.6 (1.0) and the mean (SD) HAQ score was 2.0 (0.6).   
  Differences in the baseline characteristics among the patients 
receiving different baseline DMARD co-therapies were found 
(  table 1  ). Patients receiving MTX in combination with other 
DMARDs tended to be younger, have a shorter disease dura-
tion and have fewer comorbidities than those receiving either 
no concomitant DMARDs or DMARD monotherapy. Patients 
receiving either no DMARDs or LEF with their anti-TNF 
had received the highest number of previous DMARDs at 
baseline. 
  There were also differences in the choice of anti-TNF agent 
between the different groups. Patients receiving either no 
DMARD or a DMARD monotherapy other than MTX were less 
likely to start INF than patients receiving MTX, either alone or 
in combination.   
  Treatment  persistence 
  Over a median of 2.0 years of follow-up (IQR=0.7–4.0, max 
8.1) 50% of patients discontinued their primary anti-TNF ther-
apy, including 22% for inefﬁ  cacy and 21% for adverse events 
(  table 2  ). The median overall drug survival was 3.32 years. The 
overall anti-TNF persistence (95% CI) decreased from 71% 
(71% to 72%) at year 1 to 42% (41% to 43%) at year 5 (    ﬁ  gure 1  ). 
Crude treatment persistence of each DMARD combination is 
shown in   ﬁ  gure 2  . The best overall persistence was seen among 
those patients receiving anti-TNF therapy in combination with 
MTX plus one or more other DMARD. MTX and SSZ showed 
similar overall persistence while patients receiving LEF had a 
persistence proﬁ  le which was similar to those receiving no con-
current DMARDs.       
  After adjusting for differences in baseline covariates, com-
pared with MTX, patients receiving MTX in combination with 
other DMARDs were less likely to discontinue their anti-TNF 
therapies while patients receiving SSZ or LEF monotherapy, or 
no concomitant DMARDs were more likely to discontinue their 
anti-TNF therapies (  table 3  ). Similar results were found when 
the analysis was limited by the reason for discontinuation (inef-
ﬁ  cacy or adverse events). A secondary analysis stratiﬁ  ed by anti-
TNF therapy (ETN, INF or ADA) found very similar results to 
the cohort as a whole with the exception of similar treatment 
persistence between SSZ and MTX in patients receiving ETN 
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presented anti-TNF treatment persistence up to 5 years, at which 
point <50% of patients were still receiving their ﬁ  rst anti-TNF 
therapy. 
  Our data have conﬁ  rmed the beneﬁ  ts of combining anti-TNF 
therapies with MTX. With INF, which is recommended for use 
with MTX,    23    the beneﬁ  t is felt, in part, to be due to the reduction 
of human antichimeric antibodies.    24        25    Although the mechanism 
of beneﬁ  t is less well understood with other anti-TNF agents, 
our results are in keeping with the results of both clinical trials 
and observational data.    4        26        27    
  One of the strengths of the BSRBR is its large size which 
has allowed the study of other speciﬁ  c  anti-TNF/DMARD 
combinations. Although the results can only be generalised 
to patients with high disease activity at start of treatment 
(DAS28>5.1) despite two failed DMARDs, compared with 
concurrent MTX, the combination of anti-TNF with either 
LEF or SSZ resulted in lower treatment persistence, with 
patients more likely to stop for either inefﬁ  cacy or adverse 
events. Previous reports on the beneﬁ  ts or risks of combin-
ing anti-TNF therapy with LEF have given mixed results. Two 
studies have found similar efﬁ  cacy, whether measured using 
DAS28, American College of Rheumatology scores or treat-
ment persistence, between anti-TNF in combination with 
either MTX or LEF.    7        8    A further Dutch study (n=162), which 
compared anti-TNF persistence between those receiving LEF 
and those receiving any other DMARD(s), also found simi-
lar outcomes.    28    In contrast Strangfeld   et al      9    reported higher 
discontinuation rates of anti-TNF therapies (especially with 
INF) (n=1769) when combined with LEF than when combined 
with MTX, although this did not reach statistical signiﬁ  cance. 
Other studies, the majority limited to the combination of LEF 
(  table 4  ). However, a test for interaction between SSZ and the 
anti-TNF therapies was not statistically signiﬁ  cant (p=0.09).         
  DISCUSSION 
  This analysis is the ﬁ  rst to examine and compare the effects 
of anti-TNF therapy with a wide range of different DMARD 
combinations and in particular, the effects of more than one 
DMARD in combination with anti-TNF. In addition, this study 
None 3,339 2111 1580 1212 848                  325
MTX 4,418 3069 269 1632 1060                496
SSZ 308 211 144 99 71                    18
LEF 610 379 265 180 99                    41
MTX-SSZ             902 706 544 379 242                  88  
MTX-HCQ            401 311 221 154 89 32
MTX-SSZ_HCQ   418 294 219 140 81 32
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less severe disease overall. Although the results were adjusted 
for both choice of anti-TNF therapy and year of drug start, 
these differences in outcome still persisted. With these limita-
tions in mind, the results of this study cannot be interpreted as 
indicating combination DMARD treatment should be started 
in patients currently receiving DMARD monotherapy, but 
as an indication that there is no reason to stop combination 
DMARDs (at least within the limitations of those combina-
tions analysed) because of concerns about future inefﬁ  cacy or 
safety. 
  Despite the large overall sample size, the size of some groups 
was still small, limiting statistical power in our secondary anal-
ysis stratiﬁ  ed by anti-TNF therapy. However, this study does 
remain the largest of its size and nature, with detailed follow-up 
now past 5 years for many patients. A further limitation may 
have existed in the deﬁ  nition of inefﬁ  cacy and adverse events. 
The decision to stop anti-TNF therapy and the reason for dis-
continuation was left to the treating doctor. In some cases, the 
reasons for stopping may not be completely clear and may fall 
into more than one category. However, in all cases, we asked for 
only one reason to be assigned. 
  Finally, this analysis only took into account which DMARDs 
patients were taking at baseline and can be seen as the out-
comes following the decision to treat with that DMARD or 
combination, rather than as outcomes following a given period 
of treatment (an intention-to-treat analysis). Many patients 
may have either decreased or indeed started new DMARDs 
after the introduction of anti-TNF based on initial response, 
which may have also inﬂ  uenced longer-term drug persistence. 
A future analysis that included the use of these alternative 
DMARD treatments throughout the period of follow-up may 
ﬁ  nd different results but would need an even larger sample 
size to account for the multiple possible combinations of 
treatment. 
  In conclusion, we have shown that compared with combining 
anti-TNF with MTX, combining anti-TNF with MTX in combi-
nation with one or more other DMARDs (SSZ, HCQ or both) 
resulted in better long-term treatment persistence. However, 
combination of anti-TNF with LEF and SSZ (with the exception 
of ETN+SSZ) resulted in higher rates of discontinuation owing 
to both inefﬁ  cacy and safety. As the potential for unmeasured 
confounding is present in this study, further study is required 
to understand if longer-term anti-TNF treatment persistence 
would be improved by simply stopping these DMARDs or 
whether they should be substituted, where possible, with other 
DMARDS such as MTX, if tolerated.     
with INF, have reported acceptable efﬁ  cacy, although there has 
been a concern about the safety and longer-term tolerability of 
anti-TNF when combined with LEF.    11        29     –      32    In particular, there 
has been a concern about dermatological and autoimmune 
adverse events. A small study from Leeds, UK, reported a high 
incidence of induction of antinuclear antibodies and double-
stranded DNA antibodies in patients receiving INF with LEF. 
Although there was no control group in this report, there was 
a high incidence of immune-related adverse events leading to 
anti-TNF discontinuation.    12    In the current analysis, combina-
tion of LEF with INF was less common than with either ETN 
or ADA, although a stratiﬁ  ed analysis found similar results 
across all three agents. 
  Similar results to those for LEF were found with the combina-
tion of SSZ with anti-TNF, particularly when SSZ was combined 
with the monoclonal antibodies, INF and ADA. Less has been 
published on this combination. A clinical trial found a similar 
efﬁ  cacy between ETN monotherapy and ETN+SSZ in SSZ fail-
ures.    5    In contrast, in our study, ETN+SSZ appeared to result in 
better outcomes than ETN monotherapy, although the differ-
ence in persistence between the three anti-TNF therapies did 
not reach statistical signiﬁ  cance. 
  This is the ﬁ  rst study to report on the beneﬁ  ts of combining 
anti-TNF with multiple DMARDs including MTX. Not only 
were these patients less likely to stop owing to inefﬁ  cacy, they 
were also less likely to experience adverse events leading to 
drug discontinuation. The biological mechanisms behind this 
observation remain less clear. One of the limitations of this 
study is the lack of randomisation. Therefore, in addition to 
identiﬁ  ed differences between the patients receiving different 
DMARD co-therapies, which were adjusted for in our analy-
sis, there may also have been unmeasured confounders present 
which may explain in part our ﬁ  ndings. One possible unmea-
sured confounder may be that patients able to tolerate com-
bination DMARDs before starting anti-TNF therapy may be 
more likely to tolerate new treatments in general. This hypoth-
esis is supported by the higher rate of adverse events observed 
among patients receiving no concurrent DMARD. We also 
noted that patients receiving combination DMARDs were 
more likely to be receiving ADA, which may be related to the 
timing of when they joined the register, rather than to doc-
tor or patient choice. Owing to recruitment patterns, patients 
recruited in the later years of the study (when combination 
DMARD treatment had generally become more widespread) 
were more likely to be those receiving ADA. These patients 
also had lower disease duration and therefore, may have had 
  Table  3         Cox proportional hazard estimates (95% CI) for anti-TNF therapy discontinuation   
  DMARD co-therapy at 
baseline 
  Hazard ratios (95% CIs) 
 Overall  stopping    Stopping owing to inefﬁ  cacy    Stopping owing to adverse events 
 Unadjusted   Adjusted†   Unadjusted   Adjusted†   Unadjusted   Adjusted† 
 MTX   Reference 
None 1.54 (1.43 to 1.65) 1.40 (1.30 to 1.51) 1.45 (1.30 to 1.62) 1.34 (1.20 to 1.51) 1.69 (1.52 to 1.89) 1.47 (1.30 to 1.65)
SSZ 1.22 (1.03 to 1.45) 1.23 (1.03 to 1.47) 1.34 (1.05 to 1.71) 1.34 (1.04 to 1.74) 1.16 (0.88 to 1.52) 1.21 (0.91 to 1.60)
LEF 1.50 (1.34 to 1.69) 1.41 (1.25 to 1.59) 1.64 (1.38 to 1.94) 1.58 (1.32 to 1.88) 1.47 (1.22 to 1.76) 1.34 (1.10 to 1.62)
MTX+SSZ 0.70 (0.62 to 0.79) 0.76 (0.67 to 0.86) 0.74 (0.62 to 0.88) 0.77 (0.64 to 0.92) 0.59 (0.49 to 0.73) 0.70 (0.57 to 0.86)
MTX+HCQ 0.78 (0.66 to 0.92) 0.81 (0.68 to 0.96) 0.82 (0.65 to 1.05) 0.83 (0.64 to 1.06) 0.80 (0.62 to 1.04) 0.85 (0.66 to 1.11)
MTX+SSZ+HCQ 0.82 (0.70 to 0.96) 0.80 (0.68 to 0.95) 0.80 (0.62 to 1.02) 0.75 (0.58 to 0.96) 0.83 (0.64 to 1.07) 0.87 (0.67 to 1.13)
p Value* <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
    †  Adjusted for baseline age, gender, presence of comorbidities, current smoking, number of previous DMARDs, current steroids, disease duration, baseline DAS28 and baseline HAQ. All 
models additionally stratiﬁ  ed by start year and anti-TNF agent. 
  *Test of signiﬁ  cance of difference between the different DMARD co-therapies. 
  DAS, Disease Activity Score; DMARD, disease modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; LEF, leﬂ  unomide; MTX, methotrexate; 
SSZ, sulfasalazine; TNF, tumour necrosis factor.     
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